ESSA Pharma Inc (Nasdaq: EPIX), a clinical-stage pharmaceutical company that says it is focused on developing novel therapies for the treatment of prostate cancer, announced on Monday that it has completed an underwritten public offering of 4,830,918 of its common shares.
The shares are priced at USD27 per share before underwriting discounts. The company granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The total proceeds from the offering were around USD130m. The joint book-running managers for the offering are Jefferies and Piper Sandler, while lead manager for the offering is Oppenheimer & Co and Bloom Burton Securities Inc acted as co-manager for the offering.
The company aims to use the net proceeds from the offering to fund clinical activities, chemistry, manufacturing and controls, and research and development, working capital and general corporate purposes.
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Immuron signs US distribution deal for PROIBS
Cipla partners with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in US
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease